Home > Financial Services > Investing > Mezzanine Financing > Case Study: NobelPharma Co., Ltd.

Case Study: NobelPharma Co., Ltd.

NobelPharma develops drugs targeting unmet needs, including products that have not been approved for use in Japan. The company's guiding philosophy is to develop only drugs that patients need, regardless of market sales potential. Its development potential has received considerable acclaim: in January 2008, the company received the first drug approval to be issued to a biotechnology startup in Japan, and in April 2008 NobelPharma received approval for Lunabell, a treatment for endometriosis.

The DBJ Initiative:

We identified NobelPharma's research and development capability and growth potential, and responded to its need for diversification in funding sources and better credit with an offering of stock with a redemption premium. The Japanese pharmaceutical industry is incapable of adequately meeting Japanese medicinal needs, chiefly owing to “drug lag,” a delay in the release of pharmaceuticals to the market in Japan vis-a-vis global guidelines. NobelPharma is confronting this problem head on, and we anticipate further growth and achievement on NobelPharma's part in the Japanese pharmaceuticals sector as the company improves and expands its business foundation.


Page Up